FDA to expedite review of Teva drug for movement disorder

TEL AVIV, Feb 28 (Reuters) - Israel-based Teva

Pharmaceutical Industries said on Tuesday the U.S. Food

and Drug Administration (FDA) has granted "priority review" for

its SD-809 drug to treat tardive dyskinesia with a target date

for approval by Aug. 30.

Read more